BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Sound Pharmaceuticals, Inc. Files Second IND with the FDA for the Prevention of Chemotherapy Induced Hearing Loss in Advanced Stage Cancer


7/24/2008 6:47:10 AM

SEATTLE, July 23 /PRNewswire/ -- Sound Pharmaceuticals (SPI) has filed an Investigational New Drug Application with the FDA for the clinical testing of a proprietary formulation of ebselen for the prevention of chemotherapy induced hearing loss or ototoxicity. The oral capsule containing ebselen, SPI-3005, will be tested in advanced stage lung cancer and head and neck cancer patients receiving platinum based chemotherapy. This marks the second development program for SPI to enter clinical testing for a hearing loss indication. Last year, SPI-1005, an oral capsule containing ebselen entered Phase II testing with the US Navy for the prevention and treatment of noise induced hearing loss.

Currently there are no FDA approved drugs for the prevention and treatment of drug induced hearing loss or ototoxicity. SPI hopes to address this unmet medical need with its first in class first in indication drug. Several different research groups have shown that chemotherapy treatment reduces glutathione peroxidase (GPx) activity in the mammalian inner ear resulting in hearing loss, tinnitus, vertigo and dizziness. GPx is the dominant catalytic antioxidant enzyme within the inner ear, and a loss of its activity results in irreparable damage to hair cells, neurons and non-sensory tissues that are critical for hearing and balance. "A dose limiting side effect of platinum based chemotherapies are their devastating ototoxicity and neurotoxicity, and SPI-3005 is designed to attenuate these side effects without inhibiting the therapeutic efficacy of platinum or taxane based chemotherapies," said VP Eric Lynch, PhD.

"Otoprotectants such as SPI-3005 have the potential to reduce and/or alleviate chemotherapy-induced ototoxicity, and clinical studies should be pursued," said Stephen Fausti, PhD, and Director of the National Center for Rehabilitative Auditory Research (NCRAR) at the Portland VA, Professor of Otolaryngology and Neurology at Oregon Health Sciences University.

Sound Pharmaceuticals, Inc., is a privately held biopharmaceutical company with a focus on developing the first drugs for hearing loss and brain injury. For more information please contact Jonathan Kil, MD, President and CEO, 206-634-2559 or http://www.soundpharma.com.

CONTACT: Jonathan Kil, MD, President and CEO of Sound Pharmaceuticals,
+1-206-634-2559

Web site: http://www.soundpharma.com/



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES